- Home
- ACIU vs TLSI Comparison
ACIU vs TLSI Comparison
Compare ACIU & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIU | TLSI |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 244.3M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACIU | TLSI |
|---|---|---|
| Price | $3.68 | $6.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.00 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 1.5M | 213.7K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,482,957.00 | ★ $40,207,000.00 |
| Revenue This Year | N/A | $55.06 |
| Revenue Next Year | $644.42 | $46.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $1.43 | $3.42 |
| 52 Week High | $4.00 | $7.95 |
Technical Indicators
Market Signals| Indicator | ACIU | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 43.47 |
| Support Level | $3.09 | $5.60 |
| Resistance Level | $3.73 | $7.20 |
| Average True Range (ATR) | 0.21 | 0.47 |
| MACD | 0.06 | -0.21 |
| Stochastic Oscillator | 91.86 | 22.77 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.